We've found
6,431
archived clinical trials in
Anemia
We've found
6,431
archived clinical trials in
Anemia
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Updated: 8/22/2011
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Status: Enrolling
Updated: 8/22/2011
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Updated: 8/22/2011
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Status: Enrolling
Updated: 8/22/2011
Click here to add this to my saved trials
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Updated: 9/21/2011
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated: 9/21/2011
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Updated: 9/21/2011
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated: 9/21/2011
Click here to add this to my saved trials
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Updated: 9/26/2011
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Updated: 9/26/2011
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Click here to add this to my saved trials
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Updated: 9/26/2011
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Updated: 9/26/2011
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Click here to add this to my saved trials
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Updated: 10/18/2011
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated: 10/18/2011
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Updated: 10/18/2011
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated: 10/18/2011
Click here to add this to my saved trials
Socialization of Adult Men With Congenital Hemophilia A or B
Updated: 1/13/2012
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated: 1/13/2012
Socialization of Adult Men With Congenital Hemophilia A or B
Updated: 1/13/2012
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated: 1/13/2012
Click here to add this to my saved trials
Validation of the Sickle Cell Disease Pain Burden Interview
Status: Enrolling
Updated: 2/8/2012
Updated: 2/8/2012
Validation of the Sickle Cell Disease Pain Burden Interview
Status: Enrolling
Updated: 2/8/2012
Updated: 2/8/2012
Click here to add this to my saved trials
Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Updated: 2/8/2012
Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Status: Enrolling
Updated: 2/8/2012
Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Updated: 2/8/2012
Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Status: Enrolling
Updated: 2/8/2012
Click here to add this to my saved trials
Identification of Early Predictors of Fetomaternal Hemorrhage
Updated: 2/16/2012
Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies
Status: Enrolling
Updated: 2/16/2012
Identification of Early Predictors of Fetomaternal Hemorrhage
Updated: 2/16/2012
Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies
Status: Enrolling
Updated: 2/16/2012
Click here to add this to my saved trials
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Updated: 2/21/2012
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated: 2/21/2012
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Updated: 2/21/2012
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated: 2/21/2012
Click here to add this to my saved trials
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Updated: 3/8/2012
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Status: Enrolling
Updated: 3/8/2012
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Updated: 3/8/2012
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Status: Enrolling
Updated: 3/8/2012
Click here to add this to my saved trials
Study of ACE-536 in Healthy Postmenopausal Women
Updated: 3/14/2012
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
Status: Enrolling
Updated: 3/14/2012
Study of ACE-536 in Healthy Postmenopausal Women
Updated: 3/14/2012
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
Status: Enrolling
Updated: 3/14/2012
Click here to add this to my saved trials
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Updated: 3/21/2012
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Status: Enrolling
Updated: 3/21/2012
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Updated: 3/21/2012
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Status: Enrolling
Updated: 3/21/2012
Click here to add this to my saved trials
Prevention of Iron Deficiency in Breastfed Infants
Updated: 4/26/2012
Prevention of Iron Deficiency in Breastfed Infants
Status: Enrolling
Updated: 4/26/2012
Prevention of Iron Deficiency in Breastfed Infants
Updated: 4/26/2012
Prevention of Iron Deficiency in Breastfed Infants
Status: Enrolling
Updated: 4/26/2012
Click here to add this to my saved trials
Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period
Updated: 5/31/2012
Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program
Status: Enrolling
Updated: 5/31/2012
Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period
Updated: 5/31/2012
Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program
Status: Enrolling
Updated: 5/31/2012
Click here to add this to my saved trials
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
Updated: 6/28/2012
A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol
Status: Enrolling
Updated: 6/28/2012
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
Updated: 6/28/2012
A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol
Status: Enrolling
Updated: 6/28/2012
Click here to add this to my saved trials
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Updated: 7/3/2012
An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Status: Enrolling
Updated: 7/3/2012
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Updated: 7/3/2012
An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Status: Enrolling
Updated: 7/3/2012
Click here to add this to my saved trials
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Updated: 7/11/2012
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Updated: 7/11/2012
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Click here to add this to my saved trials
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Updated: 7/11/2012
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Updated: 7/11/2012
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Click here to add this to my saved trials
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Updated: 7/20/2012
Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial
Status: Enrolling
Updated: 7/20/2012
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Updated: 7/20/2012
Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial
Status: Enrolling
Updated: 7/20/2012
Click here to add this to my saved trials
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Updated: 7/25/2012
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated: 7/25/2012
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Updated: 7/25/2012
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated: 7/25/2012
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
Updated: 8/5/2012
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
Updated: 8/5/2012
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Click here to add this to my saved trials
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Updated: 8/21/2012
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Updated: 8/21/2012
Click here to add this to my saved trials
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Updated: 8/21/2012
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Updated: 8/21/2012
Click here to add this to my saved trials
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Updated: 8/23/2012
A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Status: Enrolling
Updated: 8/23/2012
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Updated: 8/23/2012
A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Status: Enrolling
Updated: 8/23/2012
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Updated: 8/29/2012
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Click here to add this to my saved trials
Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I
Updated: 10/2/2012
RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency
Status: Enrolling
Updated: 10/2/2012
Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I
Updated: 10/2/2012
RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency
Status: Enrolling
Updated: 10/2/2012
Click here to add this to my saved trials
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Updated: 10/24/2012
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Status: Enrolling
Updated: 10/24/2012
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Updated: 10/24/2012
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Status: Enrolling
Updated: 10/24/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Updated: 11/9/2012
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Updated: 12/11/2012
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Click here to add this to my saved trials
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Updated: 1/14/2013
Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 1/14/2013
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Updated: 1/14/2013
Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 1/14/2013
Click here to add this to my saved trials
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Updated: 1/17/2013
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Status: Enrolling
Updated: 1/17/2013
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Updated: 1/17/2013
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Status: Enrolling
Updated: 1/17/2013
Click here to add this to my saved trials
Iron Depletion and Replacement in Blood Donors
Updated: 1/17/2013
Iron Depletion and Replacement in Blood Donors
Status: Enrolling
Updated: 1/17/2013
Iron Depletion and Replacement in Blood Donors
Updated: 1/17/2013
Iron Depletion and Replacement in Blood Donors
Status: Enrolling
Updated: 1/17/2013
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Updated: 1/25/2013
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Click here to add this to my saved trials